Xencor and Genentech to Collaborate to Develop Next-Generation Antibody Therapeutics Read more about Xencor and Genentech to Collaborate to Develop Next-Generation Antibody Therapeutics
Xencor and Chugai Initiate Partnership for Optimized Antibodies Read more about Xencor and Chugai Initiate Partnership for Optimized Antibodies
Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies Read more about Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies
MedImmune Licenses Xencor’s XmAb™ Technology To Create Antibody Therapeutics Against Select Tumor Targets; Fifth XmAb™ Deal For Xencor In The Last Year Read more about MedImmune Licenses Xencor’s XmAb™ Technology To Create Antibody Therapeutics Against Select Tumor Targets; Fifth XmAb™ Deal For Xencor In The Last Year
Lilly Licenses Xencor’s Immunofilter™ Technology Read more about Lilly Licenses Xencor’s Immunofilter™ Technology
Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc. Read more about Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc.
Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells Read more about Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells
Xencor Completes $6 Million Bridge Financing with Novo Nordisk and Existing Investors Read more about Xencor Completes $6 Million Bridge Financing with Novo Nordisk and Existing Investors
